Abstract
The pharmacokinetics of platinum (Pt) and cisplatin (CDDP)-DNA adducts were studied in nude mice after single-dose CDDP treatments. Whole blood, serum, kidney, lever, testis, brain, and tumor were collected at different intervals after injection of CDP at different dose levels. Pt was measured with flameless atomic absorption spectrometry (FAAS) or adsorptive voltammetry (AdV) and CDDP-DNA adducts with quantitative immunohistochemistry. The drug was immediately absorbed into the blood circulation (peak serum Pt levels were reached within 5 min) after i.p. CDDP administration, and distribution into most tissues also occurred rapidly (tissue Pt levels peaked at 15 min). With a sampling period of 7 days there was a biphasic elimination of Pt from blood, serum, and tissues. In the brain the pharmacokinetics differed with a gradual accumulation of Pt occurring during the 1st week. Formation of CDDP-DNA adducts in tissues was a slower process, with maximal levels being achieved at between 30 min and 4 h after drug administration, followed by a steady state lasting for at least 24 h. Each tissue type had its specific immunohistochemical staining pattern of adducts. With escalating CDDP doses there was a linear, or almost linear, increase in Pt concentrations and CDDP-DNA adduct levels in all sample types examined. These results suggest that a fair estimation of the amount of drug in tumor and normal tissues can be made from analysis of serum Pt at a fixed time point after a single dose of CDDP.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ali PA, Lewis DG, El-Sharkawi AM, Al-Sadhan FA, Evans CJ, Hancock DA, Dutton J (1993) Initial measurements of platinum concentration in head and neck tumors using X-ray fluorescence. Basic Life Sci 60: 281
Amlacher R, Böckel V, Mackowiak A, Stadeler M, Frankenberg D, Hoffmann H (1990) Distribution of cisplatin in tumor-free versus tumor bearing B6D2F1 mice. Arch Geschwulstforsch 60: 341
Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanism of acquired resistance. Cancer Cells 2: 35
Bacus JW, Grace LJ (1987) Optical microscope system for standardized cell measurements and analyses. Appl Optics 26: 3280
Blommaert FA, Michael C, Terheggen PMAB, Muggia FM, Kortes V, Schornagel JH, Hart AAM, Engelse L den (1993) Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 53: 5669
Boven E, Vijgh WJF van der, Nauta MM, Schlüper HMM, Pinedo HM (1985) Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45: 86
Brady HR, Zeidel ML, Kone BC, Giebisch G, Gullans SR (1993) Differential actions of cisplatin on renal proximal tubule and inner medullary collecting duct cells. J Pharmacol Exp Ther 265: 1421
Campbell AB, Kalman SM, Jacobs C (1983) Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67: 169
Desoize B, Marechal F, Millart H, Cattan A (1991) Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother 45: 203
Esposito M, Vannozzi MO, Viale M, Pellecchia C, Merlo F, Cadoni A, Cafaggi S, Parodi B, Lerza R, Poirier MC (1993)cis-Diamminedichloroplatinum(II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia. Anticancer Res 13: 1511
Fichtinger-Schepman AMJ, Veer JL van der, Hartog JHJ den, Lohman PHM, Reedijk J (1985) Adducts of the antitumor drugcis-diamminedichloroplatinum(II) with DNA: formation, identification and quantification. Biochemistry 24: 707
Fichtinger-Schepman AMJ, Vendrik CPJ, Dijk-Knijnenburg WCM van, Jong WH de, Minnen ACE van der, Claessen AME, Velde-Visser SD van der, Groot G de, Wubs KL, Steerenberg PA, Schornagel JH, Berends F (1989) Platinum concentration and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or-resistant immunoglobulin M immunocytoma. Cancer Res 49: 2862
Fichtinger-Schepman AMJ, Velde-Visser SD van der, Dijk-Knijnenburg WCM van, Oosterom AT van der, Baan RA, Berends F (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissues of cancer patients receiving chemotherapy: comparison with in vitro adduct fromation. Cancer Res 50: 7887
Fulco RA, Vannozzi M, Collecchi P, Merlo F, Parodi B, Civalleri D, Esposito M (1990) Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia. Anticancer Res 10: 1603
Johnsson A, Olsson C, Andersson H, Cavallin-Stahl E (1994) Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Cytometry 17: 142
Jonson R, Mattsson S, Unsgaard B (1988) A method for in vivo analysis of platinum after chemotherapy with cisplatin. Phys Med Biol 33: 847
Kataoka M, Kawamura M, Nishiyama Y, Fujii T, Mogami H, Itoh H, Akuta K, Akaboshi M, Kawai K, Hamamoto K (1993) Distribution of radiolabeledcis-diamminedichloroplatinum(II) on scintigraphic images in the tumor-bearing rabbit. Radiat Med 11: 173
Kubota T, Inoue S, Furukawa T, Ishibiki K, Kitajima M, Kawamura E, Hoffman RM (1993) Similarity of serum-tumor pharmacokinetics of antitumor agents in man and mice. Anticancer Res 13: 1481
Lange RC, Spencer RP, Harder HC (1973) The antitumor agent cis-Pt(NH3)2Cl2: distribution studies and dose calculation for 193mPt and 195mPt. J Nucl med 14: 191
Levi JA, Aroney RS, Dalley DN (1981) Haemolytic anaemia after cisplatin treatment. BMJ 282: 2003
Litterst CL, Gram TE, Dedrick RL, Leroy AF, Guarino AM (1976) Distribution and disposition of platinum following intravenous administration ofcis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res 36: 2340
Litterst CL, LeRoy AF, Guarino AM (1979) Disposition and distribution of platinum following parenteral administration ofcis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep 63: 1485
Los G (1990) Experimental basis of intraperitoneal chemotherapy. Doctoral thesis, Free University, Amsterdam
Los G, Mutsaers PHA, Vjgh WJF van der, Baldew GS, Graaf PW de, McVie JG (1989) Direct diffusion ofcis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380
McKay K (1993) New techniques in the pharmacokinetic analysis of cancer drugs II. The ultratrace determination of platinum in biological samples by inductively coupled plasma-mass spectrometry. Cancer Surv 17: 407
Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schachter L, Einhorn LH (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163
Nygren O, Vaughan GT, Florence TM, Morrison GMP, Warner IM, Dale LS (1990) Determination of platinum in blood by adsorptive voltammetry. Anal Chem 62: 1637
Poirier MC, Lippard SJ, Zwelling LA, Ushay HM, Kerrigan D, Thill CC, Santella RM, Grunberger D, Yuspa SH (1982) Antibodies elicited againstcis-diamminedichloroplatinum(II)-modified DNA are specific forcis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci USA 79: 6443
Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S (1992) Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52: 149
Poirier MC, Shamkhani H, Reed E, Tarone RE, Gupta-Burt S (1992) DNA adducts induced by platinum drug chemotherapeutic agents in human tissues. In: D'Amato R, Slaga TJ, Farland W, Henry C (eds) Relevance of animal studies to the evaluation of human cancer risk. Wiley-Liss, New York, p 197
Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC (1987)cis-Diamminedichloroplatinum(II)-DNA adduct formation in renal, gonadal and tumor tissues of male and female rats. Cancer Res 47: 718
Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC (1990) Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50: 2256
Singh G (1991) MtDNA as a critical target for cisplatin-induced nephrotoxicity. Proceedings, 6th international symposium on platinum and other metal coordination compounds in cancer chemotherapy, San Diego, CA, USA, January 23–26, 1991, p 284
Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, Loo TL (1982) Human tissue distribution of platinum aftercis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10: 51
Sunderman FW Jr, Sporn J, Hopfer SM, Sweeney KR, Chakraborty NG, Greenberg B (1990) Platinum in blood mononuclear cells from patients after cisplatin therapy. Ann Clin Lab Sci 20: 379
Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, Engelse L den (1987) Immunocytochemical detection of interaction products ofcis-diammindichloroplatinum(II) andcis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) with DNA in rodent tissues. Cancer Res 47: 6719
Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Naito S, Kumazawa J, Sueishi K (1993) Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans. Int Urol Nephrol 25: 215
Vadiei K, Siddik ZH, Khokhar AR, Al-Baker S, Sampedro F, Perez-Soler R (1992) Pharmacokinetics of liposome-entrappedcis-bis-neodecanoato-trans-R-R-1,2-diamminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 30: 365
Vermorken JB, Vijgh WJF van der, Klein I, Hart AAM, Gall HE, Pinedo HM (1984) Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68: 505
Vermorken JB, Vijgh WJF van der, Klein I, Gall HE, Groeningen CJ van, Hart GAM, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39: 136
Wennerberg J, Biörklund A, Tropé C (1988) The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 114: 162
Wolf W, Manaka RC (1976) Synthesis and distribution of195mPtcis-dichlorodiammineplatinum(II). J Clin Hematol Oncol 7: 79
Yasumasu T, Ueda T, Uozumi J, Mihara Y, Koikawa Y, Kumazawa J (1992) Ultrastructural alterations and DNA synthesis of renal cell nuclei following cisplatin or carboplatin injection in rats. J Pharm Pharmacol 44: 885
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnsson, A., Olsson, C., Nygren, O. et al. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother. Pharmacol. 37, 23–31 (1995). https://doi.org/10.1007/BF00685625
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685625